Vancomycin Area under the Concentration-Time Curve Estimation Using Bayesian Modeling versus First-Order...

Area of Science:

• Pharmacokinetics and Pharmacodynamics
• Clinical Pharmacy
• Health Informatics

Background:

• Vancomycin therapeutic drug monitoring is crucial for optimizing patient outcomes.
• Accurate estimation of vancomycin area under the concentration-time curve (AUC) is essential for effective dosing.
• Traditional methods for AUC calculation may be time-consuming and have limitations in data utilization.

Purpose of the Study:

• To compare the efficiency of Bayesian modeling software versus first-order pharmacokinetic (PK) equations for vancomycin AUC estimations.
• To evaluate the time required for AUC determination and subsequent regimen adjustments.
• To assess the usability of vancomycin concentrations and the incidence of acute kidney injury (AKI).

Main Methods:

• A quasi-experimental, crossover study was conducted in a tertiary care hospital.
• Vancomycin AUC monitoring was performed using both Bayesian modeling software and first-order PK equations.
• Primary endpoint: time to AUC estimation and regimen adjustment; Secondary endpoints: vancomycin concentration usability and AKI incidence.

Main Results:

• Without electronic health record (EHR) integration, Bayesian modeling was slower (9.3 min) than PK equations (6.8 min).
• With simulated EHR integration, Bayesian modeling significantly reduced time to intervention (3.8 min).
• Vancomycin concentrations were more frequently usable with Bayesian modeling (88.2%) compared to PK equations (48.3%), with no AKI cases.

Conclusions:

• Simulated EHR integration makes Bayesian software more time-efficient for vancomycin dosing decisions.
• Bayesian modeling enhances the proportion of usable vancomycin concentration data for AUC calculations.
• These findings suggest potential benefits of integrated Bayesian software in clinical practice for vancomycin management.